CD138 Protein: A Key Marker of Plasma Cells and the Cornerstone of Multiple Myeloma Diagnosis and Treatment

CD138 protein, also known as Syndecan-1, is a core member of the heparan sulfate proteoglycan family. As the most stable and specific surface marker of plasma cells, CD138 plays a pivotal role in cell adhesion, signal transduction, and microenvironment interactions. Its expression profile exhibits extreme specificity—being highly restricted to terminally differentiated plasma cells in healthy tissues while consistently overexpressed in malignant plasma cells (e.g., multiple myeloma)—making it an indispensable biomarker for the diagnosis, classification, prognosis assessment, and pathological mechanism research of plasma cell disorders. This article will delve into its molecular functions, systematically outline its associated disease spectrum, and comprehensively review its applications and challenges in basic research and clinical translation.

CD138 is a type I transmembrane proteoglycan.
Core structure:
Extracellular domain: Contains multiple sites for covalent binding of heparan sulfate (HS) and chondroitin sulfate (CS) chains. These glycosaminoglycan (GAG) chains serve as molecular platforms for CD138's interactions with numerous ligands.
Transmembrane domain: Mediates protein anchoring.
Cytoplasmic domain (C-terminus): Highly conserved, containing motifs that interact with cytoskeletal proteins and signaling molecules, participating in intracellular signal transduction.
Expression patterns:
Normal physiology: Expression is strictly limited to terminally differentiated plasma cells (antibody-secreting cells in bone marrow, lymph nodes, and spleen) and some epithelial cells (e.g., keratinocytes, epithelial basal cells).
Pathological states: Stably overexpressed in malignant plasma cell disorders (e.g., multiple myeloma). Expression may be upregulated or downregulated in certain epithelial-derived malignancies, depending on cancer type and stage.

CD138 is not merely a surface marker but participates in various physiological processes through its GAG chains and core protein:
Cell-matrix and cell-cell adhesion: Binds extracellular matrix (ECM) components (e.g., fibronectin, collagen) via HS chains, mediating the localization and retention of plasma cells in the bone marrow microenvironment.
Growth factor co-receptor function: Its HS chains can bind and concentrate growth factors (e.g., FGF, HGF, VEGF), creating local high concentrations for efficient delivery to adjacent high-affinity receptors, thereby regulating cell proliferation and survival. This is a key mechanism by which CD138 promotes tumor cell growth and drug resistance in multiple myeloma (MM).
Signal transduction: The cytoplasmic tail can bind various signaling proteins (e.g., small GTPases, protein kinase C), transmitting signals that regulate cytoskeletal rearrangement, migration, and differentiation.
Proteolytic "switch": Cell-surface CD138 can be cleaved by enzymes like matrix metalloproteinases, releasing its extracellular domain (sCD138). sCD138 acts as a competitive inhibitor, affecting related signaling pathways, and can enter circulation as a soluble biomarker.

CD138 is the "gold standard" marker for diagnosing and monitoring these diseases.
Multiple myeloma (MM):
Diagnostic cornerstone: Immunohistochemistry (IHC) or flow cytometry detection of CD138+ cells in bone marrow aspirates is fundamental for confirming MM and assessing tumor plasma cell burden. The proportion of CD138+ plasma cells is one of the core diagnostic criteria for MM.
Prognostic significance: High expression correlates with certain high-risk genetic subtypes. Persistent CD138+ cells after treatment (minimal residual disease, MRD) are a strong indicator of poor prognosis.
Pathogenic role: By binding growth factors (e.g., IGF-1, HGF) secreted by bone marrow stromal cells, CD138 activates key survival pathways like PI3K/Akt, mediating cell adhesion-dependent drug resistance and protecting tumor cells from chemotherapy.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM):
Diagnosis and risk stratification: Used to quantify clonal plasma cells, critical for distinguishing MGUS, SMM, and active MM.
Primary systemic amyloidosis (AL type):
Diagnostic value: Detects and quantifies clonal plasma cells producing amyloidogenic light chains.
Plasma cell leukemia:
Differential diagnosis: Flow cytometry detection of CD138+CD38+CD45dim/-- abnormal plasma cells in peripheral blood is diagnostic.

CD138 expression in epithelial-derived tumors exhibits "cancer type-dependent" roles, acting as either a tumor suppressor or promoter.
Poor prognostic marker:
Hepatocellular carcinoma, gastric cancer, colorectal cancer, etc.: High CD138 expression often correlates with tumor invasion, metastasis, and poor patient outcomes.
Favorable prognostic marker:
Breast cancer: In some studies, its expression is associated with well-differentiated tumors, lower metastasis risk, and better prognosis.
Mechanisms: Influences epithelial-mesenchymal transition (EMT), tumor cell migration, angiogenesis, and chemotherapy sensitivity.

Pathophysiology: At inflammatory sites (e.g., synovium in rheumatoid arthritis), plasma cells and activated B cells may express CD138, participating in local immune responses.
Soluble CD138 (sCD138): As a marker of inflammatory activity, its serum levels are elevated in certain autoimmune diseases (e.g., lupus nephritis).

Immunohistochemistry (IHC): In bone marrow biopsies or soft tissue plasmacytoma sections, anti-CD138 antibody staining (e.g., MI15) is the standard method for identifying and quantifying plasma cells.
Flow cytometry immunophenotyping:
Diagnostic subtyping: CD138 (often combined with CD38, CD45, CD19, CD56, CD27) is essential for detecting abnormal plasma cell clones and stratifying MM immunophenotypes.
Minimal residual disease (MRD) detection: Multiparameter flow cytometry (e.g., NGF) detects very low levels of CD138+ residual tumor cells post-treatment, serving as a gold standard tool for assessing therapeutic depth, predicting relapse, and guiding therapy.

Plasma cell isolation and purification: CD138 magnetic bead sorting enables high-purity isolation of normal or malignant plasma cells from bone marrow or spleen for gene expression profiling, proteomics, and functional studies.
Mechanistic research tool: Knockdown or overexpression of CD138 in cell lines elucidates its roles in MM cell adhesion, drug resistance, and signal transduction.
Potential target for drug development: Despite challenges, CD138-targeted strategies are under exploration, e.g., antibody-drug conjugates (ADCs) or bispecific antibodies.

Challenges as a therapeutic target:
Shedding: Cell-surface CD138 is easily cleaved into sCD138, leading to target loss and reduced efficacy of antibody-based drugs.
Complex biological functions: Its expression in normal epithelial tissues increases potential toxicity risks for targeted therapies.
Low internalization efficiency: As an ADC target, its natural internalization efficiency is suboptimal, limiting cytotoxic drug delivery. These factors have hindered successful CD138-targeted therapies.
Standardization of detection: Flow cytometry and IHC protocols (e.g., antibody clone selection, gating strategies, threshold settings) require further standardization for inter-laboratory comparability.

Optimizing MRD detection: Combining CD138-based flow cytometry with next-generation sequencing (NGS) for higher sensitivity and standardized MRD assessment.
Exploring novel targeting strategies:
Innovative ADC design: Developing new linkers and payloads to enhance internalization and cytotoxicity of CD138-based ADCs.
Bispecific/multispecific antibodies: Designing antibodies targeting CD138 and other MM antigens (e.g., BCMA, GPRC5D) to improve specificity and overcome antigen escape.
CAR-T/CAR-NK: Despite challenges, CD138-targeted cell therapies remain in preclinical exploration.
Targeting downstream pathways: Developing small-molecule inhibitors to disrupt CD138-mediated growth factor signaling and overcome adhesion-dependent resistance.
Liquid biopsy applications: Investigating serum sCD138 levels for disease monitoring and prognosis.
Expanding disease understanding: Using single-cell sequencing to further dissect CD138 expression and functions across plasma cell subsets and tumor microenvironment cells, revealing new biological insights.